Mozafari, Parvin, et al. “Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk During Extended Ocrelizumab Therapy in Multiple Sclerosis”. Junior Researchers, vol. 4, no. 2, July 2026, pp. 57-69, doi:10.52340/jr.2026.04.02.04.